Here's Why Cigna (CI) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CI - Cigna Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$338.33
DETAILS
HIGH:
$400.00
LOW:
$302.00
MEDIAN:
$330.00
CONSENSUS:
$338.33
UPSIDE:
19.62%
Stock News
Beacon Pointe Advisors LLC Buys Shares of 39,957 Cigna Group $CI
Beacon Pointe Advisors LLC purchased a new stake in Cigna Group (NYSE: CI) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 39,957 shares of the health services provider's stock, valued at approximately $11,015,000. Several other institutional investors have also recently
Can Cigna's Smart Coverage Help Close Health-Cost Gaps?
CI's Smart Coverage links medical and supplemental benefits, offering up to $7,000 and automated claims for costly health events.
Beneath the Headlines: An Economy in Transition, Not in Trouble
Key Takeaways The July jobs report headline (-23,000 payrolls and a combined -103,000 in prior-month revisions) glances over a more nuanced picture: layoffs remain historically low and job openings remain plentiful. This looks like a labor-supply problem, not a demand setback.
Cigna Healthcare Connects Medical and Supplemental Benefits To Help People Better Manage Unexpected Health Costs
Industry-first connected benefits experience helps people access cash benefits when they need it most and gives employers more affordable coverage options BLOOMFIELD, Conn., Aug. 26, 2026 /PRNewswire/ -- Cigna Healthcare®, the health benefits division of The Cigna Group (NYSE: CI), is introducing a new connected benefits experience that helps people pay for costs associated with unexpected or costly health events by bringing medical and supplemental health benefits together in a simpler, more personalized way.
Zacks Industry Outlook UnitedHealth, The Cigna, Humana, Centene and Molina
UnitedHealth, The Cigna, Humana, Centene and Molina have been highlighted in this Industry Outlook article.
Barrow Hanley Mewhinney & Strauss LLC Acquires New Position in Cigna Group $CI
Barrow Hanley Mewhinney and Strauss LLC purchased a new stake in Cigna Group (NYSE: CI) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 13,842 shares of the health services provider's stock, valued at approximately $3,816,000. Several other large investors have
5 HMO Stocks to Watch Amid Steady Premium Flow, Increased Digitization
An aging U.S. population, digital transformation, a diversified membership mix and strategic M&A are likely to drive the performance of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.
Cigna (CI) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Mark Cuban: "No Chance" Radiologists Get Replaced by AI. He Says the Real Target Is Elsewhere
Mark Cuban says AI will never replace radiologists, and his reasoning has nothing to do with capability. The real disruption, he argues, targets a different layer of medicine entirely, one worth hundreds of billions in enterprise value at some of the biggest names in healthcare.
B. Metzler seel. Sohn & Co. AG Takes Position in Cigna Group $CI
B. Metzler seel. Sohn and Co. AG purchased a new stake in shares of Cigna Group (NYSE: CI) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 35,312 shares of the health services provider's stock, valued at approximately $9,735,000.
Here's Why Investors Should Stay Neutral on Cigna Stock for Now
CI's growth and shareholder returns are weighed against rising costs, medical expenses and debt, keeping investors neutral for now.
Cigna: I'm Buying What Others Are Ignoring
Cigna Group remains a "Buy," with double-digit adjusted EPS growth intact and shares trading 28% below fair value. CI's Accredo and AI-powered Pharmacy Forward platforms are key growth drivers, supporting robust revenue and margin expansion through 2028. The company boasts an A- S&P credit rating, strong free cash flow, and a secure, growing dividend with low payout ratios.
Banyan Capital Management Inc. Decreases Stock Holdings in Cigna Group $CI
Banyan Capital Management Inc. decreased its stake in Cigna Group (NYSE: CI) by 3.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,148 shares of the health services provider's stock after selling 2,408 shares during the period. Cigna Group comprises about
Why Cigna (CI) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Cigna (CI) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cigna Group $CI Stock Holdings Lifted by Bank of America Corp DE
Bank of America Corp DE grew its stake in shares of Cigna Group (NYSE: CI) by 8.8% in the first quarter, according to its most recent filing with the SEC. The fund owned 3,182,083 shares of the health services provider's stock after acquiring an additional 256,677 shares during the period. Bank of America
Cigna's Valuation Gap Still Stands Out
Cigna (CI) maintains a Buy rating as valuation remains deeply discounted despite steady earnings growth and raised guidance. CI lifted 2026 adjusted EPS guidance to at least $30.45, targeting 10% EPS growth and mid-single-digit revenue growth through 2027. Capital returns continue with $6.3 billion in cash, ongoing buybacks, and a $1.56 per share dividend, supported by strong operating cash flow.
Cigna Group Q2 Earnings Call Highlights
Cigna Group NYSE: CI raised its full-year 2026 adjusted earnings outlook after reporting second-quarter results that management said exceeded expectations in both its Evernorth health services business and Cigna Healthcare insurance segment.
CI Q2 Earnings Beat Estimates on Cigna Healthcare Strength
Cigna delivers an earnings and revenue beat as Cigna Healthcare fuels growth, while the company raises its 2026 EPS outlook despite higher pharmacy costs.
Price Targets
Jefferies Downgrades CIGNA (CI) to Hold
$307.00
(was $282.06)
David Windley
·
Jefferies
Cigna downgraded to Outperform from Strong Buy at Raymond James
$320.00
(was $279.05)
Raymond James
Cigna price target raised to $362 from $337 at Baird
$362.00
(was $287.66)
Robert W. Baird
Cigna price target raised to $361 from $338 at Guggenheim
$361.00
(was $287.66)
Guggenheim
Cigna price target raised to $307 from $305 at Wells Fargo
$307.00
(was $287.66)
Wells Fargo
CIGNA (CI) PT Raised to $381 at Bernstein SocGen GroupMember Login
$381.00
(was $289.73)
Bernstein
CIGNA (CI) PT Lowered to $315 at Wolfe Research
$315.00
(was $293.83)
Justin Lake
·
Wolfe Research
Cigna price target raised to $340 from $330 at Mizuho
$340.00
(was $289.48)
Ann Hynes
·
Mizuho Securities
Barclays downgrades Cigna on lack of earnings catalysts
$304.00
(was $286.24)
Barclays
Cigna price target raised to $400 from $375 at UBS
$400.00
(was $282.02)
UBS
Cigna price target raised to $361 from $355 at Morgan Stanley
$361.00
(was $291.28)
Morgan Stanley
Cigna downgraded to Hold from Buy at Deutsche Bank
$302.00
(was $291.28)
Deutsche Bank
Cigna price target raised to $371 from $358 at Bernstein
$371.00
(was $279.35)
Bernstein
Cigna price target raised to $340 from $325 at Cantor Fitzgerald
$340.00
(was $285.11)
Sarah James
·
Raymond James
Cigna price target raised to $337 from $306 at Baird
$337.00
(was $285.60)
Robert W. Baird
Cigna price target raised to $330 from $325 at Mizuho
$330.00
(was $285.54)
Mizuho Securities
Cigna price target raised to $310 from $303 at Barclays
$310.00
(was $290.58)
Barclays
Cigna price target lowered to $330 from $333 at Jefferies
$330.00
(was $278.64)
Jefferies
Cigna price target raised to $350 from $320 at Truist
$350.00
(was $292.76)
Truist Financial
Cigna price target raised to $304 from $301 at Deutsche Bank
$304.00
(was $291.17)
Deutsche Bank